Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

被引：9

作者：

Lesieur, Auriane ^{[1
]}

Thomas, Xavier ^{[2
]}

Nibourel, Olivier ^{[1
,3
]}

Boissel, Nicolas ^{[4
]}

Fenwarth, Laurene ^{[1
,3
]}

De Botton, Stephane ^{[5
]}

Fournier, Elise ^{[1
,3
]}

Celli-Lebras, Karine ^{[4
]}

Raffoux, Emmanuel ^{[4
]}

Recher, Christian ^{[6
]}

Lambert, Juliette ^{[7
]}

Berthon, Celine ^{[3
,8
]}

Pigneux, Arnaud ^{[9
]}

Itzykson, Raphael ^{[4
]}

Turlure, Pascal ^{[10
]}

Pautas, Cecile ^{[11
]}

Vargaftig, Jacques ^{[12
]}

Preudhomme, Claude ^{[1
,3
]}

Dombret, Herve ^{[4
]}

Duployez, Nicolas ^{[1
,3
]}

机构：

[1] CHU Lille, Lab Hematol, Lille, France

[2] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Lyon, France

[3] Univ Lille, Canther Canc Heterogene Plast & Resistance Therap, Inst Rech Canc Lille, CHU Lille,Inserm,CNRS,UMR9020,UMR S 1277, Lille, France

[4] Univ Paris, St Louis Res Inst, St Louis Hosp, Dept Hematol,AP HP, Paris, France

[5] Gustave Roussy Inst, Dept Hematol, Villejuif, France

[6] Toulouse Canc Univ Inst, Dept Hematol, Toulouse, France

[7] CH Versailles, Dept Hematol, Le Chesnay, France

[8] CHU Lille, Dept Clin Hematol, Lille, France

[9] Bordeaux Haut Leveque Univ Hosp, Dept Hematol, Pessac, France

[10] Univ Limoges, CHU Limoges, Dept Hematol, Limoges, France

[11] Henri Mondor Hosp, AP HP, Dept Hematol, Creteil, France

[12] Rene Huguenin Hosp, Curie Hosp, St Cloud, France

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 06期

关键词：

NUCLEOPHOSMIN; AML;

D O I：

10.3324/haematol.2020.260133

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1767 / 1769

页数：3

共 50 条

[31] NPM mutations and not FLT3 mutations are a potential marker for monitoring minimal residual disease in acute myeloid leukemia.
Palmisano, Michela
Grafone, Tiziana
Ottaviani, Emanuela
Testoni, Nicoletta
Paolini, Stefania
Papayannidis, Cristina
Rondoni, Michela
Baccarani, Michele
Martinelli, Giovanni
BLOOD, 2006, 108 (11) : 570A - 571A
[32] Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
Suzuki, T
Kiyoi, H
Ozeki, K
Tomita, A
Suzuki, R
Kodera, Y
Miyawaki, S
Asou, N
Kuriyama, K
Yagasaki, F
Shimazaki, C
Akiyama, H
Nishimura, M
Motoji, T
Shinagawa, K
Takeshita, A
Ueda, R
Naoe, T
BLOOD, 2005, 106 (11) : 666A - 666A
[33] Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients
Shi, Yu
Chen, Xiao
Jin, Huimin
Zhu, Liying
Hong, Ming
Zhu, Yu
Wu, Yujie
Qiu, Hairong
Wang, Yan
Sun, Qian
Jin, Hui
Li, Jianyong
Qian, Sixuan
Qiao, Chun
ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2323 - 2335
[34] Verification of quantitative polymerase chain reaction method for monitoring minimal residual disease in chronic myeloid leukemia
Svabek, Z. Tkalcic
Paro, M. M. Kardum
Horvat, M.
Smoljanovic, I. Mandac
Martinovic, M.
Kristo, D. Radic
CLINICA CHIMICA ACTA, 2024, 558
[35] Postinduction Minimal Residual Disease Monitoring by Polymerase Chain Reaction in Children With Acute Lymphoblastic Leukemia
Paganin, Maddalena
Fabbri, Giulia
Conter, Valentino
Barisone, Elena
Polato, Katia
Cazzaniga, Giovanni
Giraldi, Eugenia
Fagioli, Franca
Arico, Maurizio
Valsecchi, Maria Grazia
Basso, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) : 3553 - +
[36] c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation
Lyapichev, Kirill A.
Behdad, Amir
BLOOD, 2025, 145 (05) : 547 - 547
[37] MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1: PROSPECTICAL EVALUATION AND MRD DIRECTED THERAPY
Guolo, F.
Minetto, P.
Clavio, M.
Di Grazia, C.
Colombo, N.
Raiola, A. M.
Guardo, D.
Coviello, E.
Ballerini, F.
Miglino, M.
Angelucci, E.
Bacigalupo, A.
Lemoli, R. M.
Gobbi, M.
HAEMATOLOGICA, 2017, 102 : 47 - 47
[38] Next-Generation Sequencing of NPM1 for Minimal Residual Disease Monitoring in Leukemia Patients
Carson, A. R.
Xie, Z.
McClain, V.
Miller, J. E.
Stenzel, T.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 967 - 967
[39] NPM1 Minimal Residual Disease Detection at Any Time by Clinical Next Generation Sequencing Predicts Poor Survival in Acute Myeloid Leukemia
Sallman, D.
Xie, Z.
Chan, O.
Shao, R.
Song, J.
Hussaini, M. O.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S83 - S83
[40] Minimal residual disease detection in acute myeloid leukemia (AML) by mutant nucleophosmin (NPM1) early predicts impending relapse
Shayegi, N.
Kramer, M.
Bornhaeuser, M.
Schaich, M.
Schetelig, J.
Platzbecker, U.
Roellig, C.
Ehninger, G.
Thiede, C.
ONKOLOGIE, 2011, 34 : 298 - 298

← 1 2 3 4 5 →